DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/sbczk8/pharmapoint) has announced the addition of the "PharmaPoint: Alzheimer's Disease - Global Drug Forecast and Market Analysis to 2022" report to their offering.
Global Alzheimer's Disease Drug Sales by Region, 2012-2022
The combined sales of medications carrying an indication in AD were estimated at $4.0 billion in 2012. By 2022, we project AD drug sales to grow to $6.5 billion, with a Compound Annual Growth Rate (CAGR) of 5.0% over the course of the decade. These estimates cover the sales in the nine major markets (9MM) included in this report: the US, France, Germany, Italy, Spain, the UK, Japan, China, and India.
We predict that the following parameters will drive expansion in these markets:
- Growing elderly populations
- Diagnostic improvements
- Increasing levels of awareness
- Introduction of biologic medicines
- Expanded accessibility of care
Symptomatic Therapies Dominate the Alzheimer's Disease Drug Market
The pharmaceutical market for AD is composed solely of symptomatic therapies that confer small improvements in cognition and function, but the benefit from these medications cannot be maintained long term. All AD patients ultimately outgrow the effects of pharmacotherapy as their condition worsens. In recognition of the unmet therapeutic needs in this market, current research and development (R&D) efforts are focused on developing drugs with novel mechanisms that slow or halt the progression of the disease. Several key players in the industry have concentrated on the two key features that are present in the AD-diseased brain: amyloid plaques and neurofibrillary tangles (NFTs) composed of tau proteins. However, it has yet to be proven that preventing the formation of these structures alone will prompt clinical improvements. Given the growing list of late-stage clinical trial failures, AD pharmacotherapy has proven to be a difficult challenge, but those agents that do emerge from the developmental landscape are poised to make billions of dollars annually.
The current AD drug armamentarium consists of four medications and has been without any new agents in nearly a decade. The absence of new market competition has allowed for the manufacturers of these four agents to retain strong sales throughout their lifespans. Japan's Eisai; the Swiss pharmaceutical giant, Novartis; the German-headquartered Merz Pharmaceuticals; and Johnson & Johnson's (J&J's) Janssen Pharmaceuticals have shared the entirety of drug sales in this space, but these medications have either lost patent protection in several regions or their patent expiries are impending. By now, physicians have an established familiarity with these courses of therapy, and these companies have fostered their relationship with prescribers by offering their products in different dosage forms that may assist with drug delivery, tolerability, and ease of administration. With disease-modifying medications poised to emerge during the forecast period, these companies are likely to lose their dominance of the market.
Symptomatic therapies with improved drug designs and novel mechanisms will retain their utility in AD. There is ample space within the AD drug market for therapies that can maintain their palliative effects with greater efficiency and duration.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
5 Disease Management
6 Competitive Assessment
7 Opportunity and Unmet Need
8 Pipeline Assessment
9 Current and Future Players
10 Market Outlook
- F. Hoffman-La Roche (Roche)
- AbbVie (Abbott Laboratories)
- Eli Lilly
- Baxter International
- EnVivo Pharmaceuticals
- Adamas Pharmaceuticals
- Johnson & Johnson
For more information visit http://www.researchandmarkets.com/research/sbczk8/pharmapoint